Role of Teriparatide in Osteoporosis Management, Including CKD Patients
Teriparatide is a potent anabolic agent that reduces vertebral fractures by 74% and nonvertebral fractures by 39%, making it the preferred choice for patients with severe osteoporosis at very high fracture risk, particularly those who have failed bisphosphonate therapy or have contraindications to antiresorptive agents. 1
Primary Indications and Efficacy
Teriparatide (PTH 1-34) works by preferentially stimulating osteoblastic activity over osteoclastic activity, building new bone on both trabecular and cortical surfaces. The evidence demonstrates:
- 74% reduction in vertebral fractures (HR 0.26; 95% CI 0.18-0.39)
- 39% reduction in nonvertebral fractures (HR 0.61; 95% CI 0.44-0.85)
- Superior to risedronate in the VERO trial for patients at very high fracture risk 1
When to Choose Teriparatide
Use teriparatide as first-line therapy when:
- Patients have severe osteoporosis with multiple vertebral fractures
- Very high fracture risk exists (T-score ≤-3.0 with fractures)
- Patients continue losing bone or fracture despite bisphosphonate therapy
- Glucocorticoid-induced osteoporosis with high fracture risk 1
Critical Treatment Parameters
Duration and Sequential Therapy
Limit teriparatide to maximum 24 months lifetime use due to black box warning for osteosarcoma (though only one case reported in >1 million human users since 2002). 1
Always follow teriparatide with antiresorptive therapy (bisphosphonate, denosumab, raloxifene, or HT) because bone gains are rapidly lost within 1 year of discontinuation without subsequent treatment. 1
Practical Considerations
- Daily subcutaneous injection (20 mcg) - adherence may be challenging
- Check serum calcium before initiating - contraindicated if elevated 1
- Monitor for hypercalcemia during treatment
- Common side effects: dizziness, leg cramps (generally mild) 1
Special Population: Chronic Kidney Disease
CKD Stages 3a-3b (eGFR 30-59 mL/min)
Teriparatide can be used with standard dosing in mild-to-moderate CKD when:
- No significant biochemical abnormalities of CKD-MBD exist
- Calcium and phosphate levels are controlled
- PTH is not severely elevated 2
Advanced CKD (Stages 4-5 and Dialysis)
Exercise extreme caution - the evidence is mixed and limited:
Pharmacokinetic concerns:
- AUC increases 73% and half-life increases 77% in severe renal impairment (CrCl <30 mL/min) 3
- Unknown effects on underlying metabolic bone disease in chronic renal impairment 3
Clinical considerations:
- Consider bone biopsy to determine bone turnover status before treatment 2
- Most beneficial for adynamic bone disease (low turnover) where teriparatide's anabolic effect is theoretically advantageous 4
- Avoid in high-turnover disease where secondary hyperparathyroidism already drives excessive bone remodeling
- Risk of hypercalcemia is 22.2% in advanced CKD patients, related to calcium-phosphate metabolism disturbances 5
Recent comparative data suggests:
- Romosozumab may be superior to teriparatide in CKD patients, showing lower vertebral fracture risk (HR 0.64) and better cardiovascular safety 6
- Alendronate was more effective than teriparatide for fracture prevention in CKD stages 3b/4 in some studies 5
Kidney Transplant Recipients
Teriparatide shows particular promise in this population:
- Significant BMD improvements at lumbar spine (+11%) and total hip (+11%) 7, 8
- Well-tolerated with no apparent excess risk to graft function 8
- Ideal for low bone turnover disease common post-transplant 7
- 90% of treated patients had prior fragility fractures, demonstrating use in very high-risk patients 8
Critical Contraindications and Warnings
Absolute contraindications:
- Elevated baseline serum calcium 1
- Pediatric patients (open epiphyses - higher osteosarcoma risk) 3
- Pregnancy and breastfeeding 3
Relative contraindications in CKD:
- Severe hyperparathyroidism (PTH >600 pg/mL)
- Uncontrolled hyperphosphatemia
- High bone turnover disease on biopsy 2
Efficacy After Prior Bisphosphonate Use
Teriparatide remains effective after bisphosphonate therapy, though:
- Onset may be somewhat delayed
- Magnitude of effect may be slightly blunted
- VERO trial subgroup analysis showed similar fracture reductions in prior bisphosphonate users versus treatment-naive patients 1
Algorithm for Decision-Making
Step 1: Assess fracture risk severity
- Very high risk (multiple vertebral fractures, T-score ≤-3.0) → Consider teriparatide first-line
Step 2: Evaluate renal function
- eGFR ≥30: Standard approach
- eGFR <30: Check calcium, phosphate, PTH; consider bone biopsy
Step 3: Determine bone turnover status (if CKD stage 4-5)
- Low turnover/adynamic → Teriparatide may be beneficial
- High turnover → Avoid teriparatide; use calcimimetics or antiresorptives
Step 4: Plan sequential therapy
- Prescribe for maximum 18-24 months
- Transition immediately to antiresorptive agent upon completion
Step 5: Monitor
- Serum calcium at baseline and periodically
- BMD at 12-24 months
- Fracture occurrence